Desidustat vs Roxadustat

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Kidney Disease

Shared mechanism: HIF prolyl hydroxylase (HIF-PH1/2/3) · full Chronic Kidney Disease pipeline

Desidustat · Oxemia

Marketed by Zydus Lifesciences and partners

Phase 3 in Chronic Kidney Diseasesmall molecule
Partial signal

NCT04012957 · Phase 3 · completed

The study was randomized and used an active darbepoetin comparator, but it was open-label and its primary outcome was change in hemoglobin, a surrogate laboratory measure rather than a hard clinical or endoscopic outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Hemoglobin level (24 weeks): Change in hemoglobin baseline to week 16-24: desidustat +0.95 g/dL vs epoetin alfa +0.80 g/dL (difference 0.14 g/dL, 95% CI -0.13 to 0.42), met prespecified noninferiority margin; hemoglobin responders 59.22% desidustat vs 48.37% epoetin alfa (p=0.0382) (met)

Result source: NCT04215120

Roxadustat · Evrenzo

Marketed by Kyntra Bio and partners

Phase 3 in Chronic Kidney Diseasesmall molecule
Reliable signal

NCT01750190 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled Phase 3 trial in 922 non-dialysis CKD patients with anemia. The two primary efficacy endpoints—mean change in hemoglobin over weeks 28-52 and hemoglobin response during the first 24 weeks—were both statistically significant and strongly favored roxadustat over placebo (p<0.0001 for both). The study was adequately powered and used a hard hemoglobin-based clinical endpoint, supporting a strong design and result.

Next expected readout: October 2027 · NCT05970172 (registry estimate)

Reported efficacy

United States (US FDA) Submission: Mean Change From Baseline in Hb (g/dL) Over Weeks 28 to 52 Regardless of Rescue Therapy (Baseline (Day 1, Week 0), Weeks 28 to 52); Ex-US Submission: Number (%) of Participants Who Achieved a Hb Response During the First 24-Weeks of Treatment Censoring for Rescue Therapy (Baseline up to Week 24): Mean hemoglobin change over Weeks 28-52: 2.00 g/dL roxadustat vs 0.16 g/dL placebo; least-squares mean difference 1.85 g/dL (95% CI 1.735-1.967; p<0.0001). Hemoglobin response during the first 24 weeks: 523/608 roxadustat vs 20/305 placebo; odds ratio 77.56 (95% CI 44.73-134.48; p<0.0001). (met)

Result source: NCT01750190

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDesidustatRoxadustat
Kidney composite outcome—Not posted · NCT04012957—Trial running · NCT05970172
UACR, % change—Not posted · NCT04012957—Trial running · NCT05970172
eGFR slope—Not posted · NCT04012957-2.6 vs -3.2+0.6 vs placebon 389NCT01887600
Haemoglobin, change1.9 vs 1.8avs darbepoetinNCT04012957
1 other result
2 vs 0.2+1.8 vs placebowk 52 · n 616NCT01750190
169 other results
  • 1.8 vs 0.4 wk 52 · n 1334 · Phase 3 · primary NCT02174627
  • 2.0 vs 0.3 n 312 · Phase 3 · primary NCT01887600
  • 2.6 vs 2.4 wk 52 · n 522 · Phase 3 · primary NCT02052310
  • 0.4 vs -0.1 wk 52 · n 370 · Phase 3 · primary NCT02273726
  • 0.4 vs 0.2 wk 52 · n 413 · Phase 3 · primary NCT02278341
  • 0.4 vs 0.2 wk 36 · n 354 · Phase 3 · primary NCT02278341
  • 0.8 vs 0.7 n 1003 · Phase 3 · primary NCT02174731
  • 0.5 vs -0.0 wk 36 · n 303 · Phase 3 · primary NCT02273726
  • 1.9 vs 0.5 wk 104 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.3 wk 100 · n 389 · Phase 3 · secondary NCT01887600
  • 1.7 vs 0.1 wk 96 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.4 wk 92 · n 389 · Phase 3 · secondary NCT01887600
  • 1.6 vs 0.4 wk 88 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.5 wk 84 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.3 wk 80 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.7 wk 76 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.3 wk 72 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.4 wk 68 · n 389 · Phase 3 · secondary NCT01887600
  • 1.6 vs 0.2 wk 64 · n 389 · Phase 3 · secondary NCT01887600
  • 2.0 vs 0.4 wk 60 · n 389 · Phase 3 · secondary NCT01887600
  • 1.7 vs 0.1 wk 56 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.3 wk 52 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.6 wk 52 · n 213 · Phase 3 · secondary NCT02174627
  • 2.0 vs 0.3 wk 44 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.2 wk 40 · n 389 · Phase 3 · secondary NCT01887600
  • 2.0 vs 0.2 wk 36 · n 608 · Phase 3 · secondary NCT01750190
  • 2.0 vs 0.2 wk 52 · n 156 · Phase 3 · secondary NCT01750190
  • 1.7 vs 0.2 wk 48 · n 389 · Phase 3 · secondary NCT01887600
  • 2.1 vs 0.4 wk 36 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.3 wk 32 · n 389 · Phase 3 · secondary NCT01887600
  • 2.0 vs 0.4 wk 28 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.4 wk 24 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.2 wk 22 · n 389 · Phase 3 · secondary NCT01887600
  • 2.2 vs 0.4 wk 20 · n 389 · Phase 3 · secondary NCT01887600
  • 2.1 vs 0.2 wk 18 · n 389 · Phase 3 · secondary NCT01887600
  • 2.4 vs 0.4 wk 16 · n 389 · Phase 3 · secondary NCT01887600
  • 2.2 vs 0.2 wk 14 · n 389 · Phase 3 · secondary NCT01887600
  • 2.4 vs 0.3 wk 12 · n 389 · Phase 3 · secondary NCT01887600
  • 2.1 vs 0.2 wk 10 · n 389 · Phase 3 · secondary NCT01887600
  • 2.2 vs 0.2 wk 8 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.1 wk 6 · n 389 · Phase 3 · secondary NCT01887600
  • 1.6 vs 0.1 wk 4 · n 389 · Phase 3 · secondary NCT01887600
  • 1.0 vs 0.0 wk 2 · n 389 · Phase 3 · secondary NCT01887600
  • 0.4 vs -0.0 wk 1 · n 389 · Phase 3 · secondary NCT01887600
  • 2.1 vs 0.5 n 311 · Phase 3 · secondary NCT01887600
  • 2.0 vs 0.4 n 312 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.3 n 291 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.3 n 124 · Phase 3 · secondary NCT01887600
  • 0.2 vs 0.1 wk 104 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 100 · n 413 · Phase 3 · secondary NCT02278341
  • 0.1 vs -0.1 wk 96 · n 413 · Phase 3 · secondary NCT02278341
  • 0.4 vs 0.2 wk 92 · n 413 · Phase 3 · secondary NCT02278341
  • 0.0 vs -0.0 wk 88 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 84 · n 413 · Phase 3 · secondary NCT02278341
  • 0.1 vs -0.0 wk 80 · n 413 · Phase 3 · secondary NCT02278341
  • 0.4 vs 0.2 wk 76 · n 413 · Phase 3 · secondary NCT02278341
  • 0.1 vs -0.0 wk 72 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 68 · n 413 · Phase 3 · secondary NCT02278341
  • 0.2 vs -0.1 wk 64 · n 413 · Phase 3 · secondary NCT02278341
  • 0.4 vs 0.2 wk 60 · n 413 · Phase 3 · secondary NCT02278341
  • 0.2 vs 0.1 wk 56 · n 413 · Phase 3 · secondary NCT02278341
  • 2.6 vs 2.4 wk 52 · n 490 · Phase 3 · secondary NCT02052310
  • 0.4 vs 0.2 wk 52 · n 413 · Phase 3 · secondary NCT02278341
  • 0.2 vs 0.1 wk 48 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.3 wk 44 · n 413 · Phase 3 · secondary NCT02278341
  • 0.2 vs 0.1 wk 40 · n 413 · Phase 3 · secondary NCT02278341
  • 0.5 vs 0.2 wk 36 · n 413 · Phase 3 · secondary NCT02278341
  • 0.4 vs 0.1 wk 34 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 32 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 30 · n 413 · Phase 3 · secondary NCT02278341
  • 0.5 vs 0.3 wk 28 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 26 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 24 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 22 · n 413 · Phase 3 · secondary NCT02278341
  • 0.5 vs 0.2 wk 20 · n 413 · Phase 3 · secondary NCT02278341
  • 0.4 vs 0.0 wk 18 · n 413 · Phase 3 · secondary NCT02278341
  • 0.6 vs 0.2 wk 16 · n 413 · Phase 3 · secondary NCT02278341
  • 0.5 vs 0.0 wk 14 · n 413 · Phase 3 · secondary NCT02278341
  • 0.7 vs 0.1 wk 12 · n 413 · Phase 3 · secondary NCT02278341
  • 0.6 vs -0.0 wk 10 · n 413 · Phase 3 · secondary NCT02278341
  • 0.8 vs 0.1 wk 8 · n 413 · Phase 3 · secondary NCT02278341
  • 0.7 vs -0.0 wk 7 · n 413 · Phase 3 · secondary NCT02278341
  • 0.9 vs 0.1 wk 6 · n 413 · Phase 3 · secondary NCT02278341
  • 0.7 vs -0.0 wk 5 · n 413 · Phase 3 · secondary NCT02278341
  • 0.8 vs 0.1 wk 4 · n 413 · Phase 3 · secondary NCT02278341
  • 0.6 vs 0.1 wk 3 · n 413 · Phase 3 · secondary NCT02278341
  • 0.9 vs 0.7 n 836 · Phase 3 · secondary NCT02174731
  • 2.3 vs 2.5 wk 24 · n 228 · Phase 3 · secondary NCT02052310
  • 0.6 vs -0.0 wk 24 · n 189 · Phase 3 · secondary NCT02273726
  • 0.5 vs 0.1 wk 2 · n 413 · Phase 3 · secondary NCT02278341
  • 0.2 vs 0.1 wk 1 · n 413 · Phase 3 · secondary NCT02278341
  • 0.8 vs 0.6 n 280 · Phase 3 · secondary NCT02174731
  • 2.7 vs 2.5 n 435 · Phase 3 · secondary NCT02052310
  • 1.2 vs 0.0 2.0 mg/kg BIW · wk 8 · n 9 · Phase 2 · primary NCT00761657
  • 1.5 vs 0.0 2.0 mg/kg TIW · wk 8 · n 11 · Phase 2 · primary NCT00761657
  • 0.8 vs 0.0 1.5 mg/kg BIW · wk 8 · n 10 · Phase 2 · primary NCT00761657
  • 1.3 vs 0.0 1.5 mg/kg TIW · wk 8 · n 11 · Phase 2 · primary NCT00761657
  • 0.5 vs 0.0 1.0 mg/kg BIW · wk 8 · n 5 · Phase 2 · primary NCT00761657
  • 0.1 vs 0.0 1.0 mg/kg TIW · wk 8 · n 5 · Phase 2 · primary NCT00761657
  • 0.6 vs 0.0 0.7 mg/kg BIW · wk 8 · n 10 · Phase 2 · primary NCT00761657
  • 0.2 vs 0.0 0.7 mg/kg TIW · wk 8 · n 12 · Phase 2 · primary NCT00761657
  • 0.7 vs -2.5 2.0 mg/kg TIW · wk 7 · n 9 · Phase 2 · secondary NCT01147666
  • -2.0 vs -2.4 2.0 mg/kg TIW · wk 12 · n 3 · Phase 2 · secondary NCT01147666
  • -0.4 vs -2.5 1.8 mg/kg TIW · wk 20 · n 6 · Phase 2 · secondary NCT01147666
  • -0.6 vs -2.5 1.8 mg/kg TIW · wk 20 · n 11 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 1.8 mg/kg TIW · wk 19 · n 6 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 1.8 mg/kg TIW · wk 19 · n 11 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 1.8 mg/kg TIW · wk 17 · n 6 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 1.8 mg/kg TIW · wk 17 · n 11 · Phase 2 · secondary NCT01147666
  • 0.5 vs -2.4 1.8 mg/kg TIW · wk 14 · n 6 · Phase 2 · secondary NCT01147666
  • -0.0 vs -2.4 1.8 mg/kg TIW · wk 14 · n 11 · Phase 2 · secondary NCT01147666
  • 0.3 vs -2.4 1.8 mg/kg TIW · wk 12 · n 6 · Phase 2 · secondary NCT01147666
  • 0.0 vs -2.4 1.8 mg/kg TIW · wk 12 · n 11 · Phase 2 · secondary NCT01147666
  • 0.6 vs -2.4 1.8 mg/kg TIW · wk 10 · n 6 · Phase 2 · secondary NCT01147666
  • 0.2 vs -2.4 1.8 mg/kg TIW · wk 10 · n 11 · Phase 2 · secondary NCT01147666
  • 0.5 vs -2.4 1.8 mg/kg TIW · wk 8 · n 6 · Phase 2 · secondary NCT01147666
  • 0.1 vs -2.4 1.8 mg/kg TIW · wk 8 · n 11 · Phase 2 · secondary NCT01147666
  • 0.3 vs -2.5 1.8 mg/kg TIW · wk 7 · n 11 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.5 1.8 mg/kg TIW · wk 7 · n 11 · Phase 2 · secondary NCT01147666
  • 0.9 vs -2.5 1.5 mg/kg TIW · wk 7 · n 10 · Phase 2 · secondary NCT01147666
  • -0.6 vs -2.5 1.3 mg/kg TIW · wk 20 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 1.3 mg/kg TIW · wk 19 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 1.3 mg/kg TIW · wk 17 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 1.3 mg/kg TIW · wk 14 · n 11 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 1.3 mg/kg TIW · wk 12 · n 11 · Phase 2 · secondary NCT01147666
  • -0.2 vs -2.4 1.3 mg/kg TIW · wk 10 · n 11 · Phase 2 · secondary NCT01147666
  • 0.0 vs -2.4 1.3 mg/kg TIW · wk 8 · n 11 · Phase 2 · secondary NCT01147666
  • -0.2 vs -2.5 1.3 mg/kg TIW · wk 7 · n 11 · Phase 2 · secondary NCT01147666
  • -0.4 vs -2.5 1.0 mg/kg TIW · wk 7 · n 9 · Phase 2 · secondary NCT01147666
  • -0.8 vs -2.5 Weight Tiered 70-100-150 mg · wk 20 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.5 Weight Tiered 70-120-200 mg · wk 20 · n 10 · Phase 2 · secondary NCT01147666
  • -0.6 vs -2.5 Weight Tiered 70-120-200 mg · wk 20 · n 10 · Phase 2 · secondary NCT01147666
  • -0.8 vs -2.4 Weight Tiered 70-100-150 mg · wk 19 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 19 · n 10 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 Weight Tiered 70-120-200 mg · wk 19 · n 10 · Phase 2 · secondary NCT01147666
  • -0.5 vs -2.4 Weight Tiered 70-100-150 mg · wk 17 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 17 · n 10 · Phase 2 · secondary NCT01147666
  • 0.0 vs -2.4 Weight Tiered 70-120-200 mg · wk 17 · n 10 · Phase 2 · secondary NCT01147666
  • -0.4 vs -2.4 Weight Tiered 70-100-150 mg · wk 14 · n 11 · Phase 2 · secondary NCT01147666
  • -0.2 vs -2.4 Weight Tiered 70-120-200 mg · wk 14 · n 10 · Phase 2 · secondary NCT01147666
  • 0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 14 · n 10 · Phase 2 · secondary NCT01147666
  • -0.6 vs -2.4 Weight Tiered 70-100-150 mg · wk 12 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 12 · n 10 · Phase 2 · secondary NCT01147666
  • 0.4 vs -2.4 Weight Tiered 70-120-200 mg · wk 12 · n 10 · Phase 2 · secondary NCT01147666
  • -0.6 vs -2.4 Weight Tiered 70-100-150 mg · wk 10 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 10 · n 10 · Phase 2 · secondary NCT01147666
  • 0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 10 · n 10 · Phase 2 · secondary NCT01147666
  • -0.5 vs -2.4 Weight Tiered 70-100-150 mg · wk 8 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 8 · n 10 · Phase 2 · secondary NCT01147666
  • 0.2 vs -2.4 Weight Tiered 70-120-200 mg · wk 8 · n 10 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.5 Weight Tiered 70-100-150 mg · wk 7 · n 11 · Phase 2 · secondary NCT01147666
  • -0.5 vs -2.5 Weight Tiered 70-120-200 mg · wk 7 · n 10 · Phase 2 · secondary NCT01147666
  • 0.2 vs -2.5 Weight Tiered 70-120-200 mg · wk 7 · n 10 · Phase 2 · secondary NCT01147666
  • 0.1 vs -2.5 2.0 mg/kg · wk 20 · n 2 · Phase 2 · secondary NCT01147666
  • -2.8 vs -2.5 2.0 mg/kg TIW · wk 20 · n 3 · Phase 2 · secondary NCT01147666
  • 0.1 vs -2.4 2.0 mg/kg · wk 19 · n 2 · Phase 2 · secondary NCT01147666
  • -3.0 vs -2.4 2.0 mg/kg TIW · wk 19 · n 3 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 2.0 mg/kg · wk 17 · n 2 · Phase 2 · secondary NCT01147666
  • -2.7 vs -2.4 2.0 mg/kg TIW · wk 17 · n 3 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 2.0 mg/kg · wk 14 · n 2 · Phase 2 · secondary NCT01147666
  • -2.3 vs -2.4 2.0 mg/kg TIW · wk 14 · n 3 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 2.0 mg/kg · wk 12 · n 2 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 2.0 mg/kg · wk 10 · n 2 · Phase 2 · secondary NCT01147666
  • -1.5 vs -2.4 2.0 mg/kg TIW · wk 10 · n 3 · Phase 2 · secondary NCT01147666
  • 0.1 vs -2.4 2.0 mg/kg · wk 8 · n 2 · Phase 2 · secondary NCT01147666
  • -0.9 vs -2.4 2.0 mg/kg TIW · wk 8 · n 3 · Phase 2 · secondary NCT01147666
  • 0 vs -2.5 2.0 mg/kg · wk 7 · n 2 · Phase 2 · secondary NCT01147666
  • -0.9 vs -2.5 2.0 mg/kg TIW · wk 7 · n 3 · Phase 2 · secondary NCT01147666
  • -2.6 vs -2.5 1.5 mg/kg TIW · wk 7 · n 1 · Phase 2 · secondary NCT01147666

Kidney composite outcome

Desidustat
—Not posted · NCT04012957
Roxadustat
—Trial running · NCT05970172

UACR, % change

Desidustat
—Not posted · NCT04012957
Roxadustat
—Trial running · NCT05970172

eGFR slope

Desidustat
—Not posted · NCT04012957
Roxadustat
-2.6 vs -3.2+0.6 vs placebon 389NCT01887600

Haemoglobin, change

Desidustat
1.9 vs 1.8avs darbepoetinNCT04012957
1 other result
Roxadustat
2 vs 0.2+1.8 vs placebowk 52 · n 616NCT01750190
169 other results
  • 1.8 vs 0.4 wk 52 · n 1334 · Phase 3 · primary NCT02174627
  • 2.0 vs 0.3 n 312 · Phase 3 · primary NCT01887600
  • 2.6 vs 2.4 wk 52 · n 522 · Phase 3 · primary NCT02052310
  • 0.4 vs -0.1 wk 52 · n 370 · Phase 3 · primary NCT02273726
  • 0.4 vs 0.2 wk 52 · n 413 · Phase 3 · primary NCT02278341
  • 0.4 vs 0.2 wk 36 · n 354 · Phase 3 · primary NCT02278341
  • 0.8 vs 0.7 n 1003 · Phase 3 · primary NCT02174731
  • 0.5 vs -0.0 wk 36 · n 303 · Phase 3 · primary NCT02273726
  • 1.9 vs 0.5 wk 104 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.3 wk 100 · n 389 · Phase 3 · secondary NCT01887600
  • 1.7 vs 0.1 wk 96 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.4 wk 92 · n 389 · Phase 3 · secondary NCT01887600
  • 1.6 vs 0.4 wk 88 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.5 wk 84 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.3 wk 80 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.7 wk 76 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.3 wk 72 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.4 wk 68 · n 389 · Phase 3 · secondary NCT01887600
  • 1.6 vs 0.2 wk 64 · n 389 · Phase 3 · secondary NCT01887600
  • 2.0 vs 0.4 wk 60 · n 389 · Phase 3 · secondary NCT01887600
  • 1.7 vs 0.1 wk 56 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.3 wk 52 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.6 wk 52 · n 213 · Phase 3 · secondary NCT02174627
  • 2.0 vs 0.3 wk 44 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.2 wk 40 · n 389 · Phase 3 · secondary NCT01887600
  • 2.0 vs 0.2 wk 36 · n 608 · Phase 3 · secondary NCT01750190
  • 2.0 vs 0.2 wk 52 · n 156 · Phase 3 · secondary NCT01750190
  • 1.7 vs 0.2 wk 48 · n 389 · Phase 3 · secondary NCT01887600
  • 2.1 vs 0.4 wk 36 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.3 wk 32 · n 389 · Phase 3 · secondary NCT01887600
  • 2.0 vs 0.4 wk 28 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.4 wk 24 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.2 wk 22 · n 389 · Phase 3 · secondary NCT01887600
  • 2.2 vs 0.4 wk 20 · n 389 · Phase 3 · secondary NCT01887600
  • 2.1 vs 0.2 wk 18 · n 389 · Phase 3 · secondary NCT01887600
  • 2.4 vs 0.4 wk 16 · n 389 · Phase 3 · secondary NCT01887600
  • 2.2 vs 0.2 wk 14 · n 389 · Phase 3 · secondary NCT01887600
  • 2.4 vs 0.3 wk 12 · n 389 · Phase 3 · secondary NCT01887600
  • 2.1 vs 0.2 wk 10 · n 389 · Phase 3 · secondary NCT01887600
  • 2.2 vs 0.2 wk 8 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.1 wk 6 · n 389 · Phase 3 · secondary NCT01887600
  • 1.6 vs 0.1 wk 4 · n 389 · Phase 3 · secondary NCT01887600
  • 1.0 vs 0.0 wk 2 · n 389 · Phase 3 · secondary NCT01887600
  • 0.4 vs -0.0 wk 1 · n 389 · Phase 3 · secondary NCT01887600
  • 2.1 vs 0.5 n 311 · Phase 3 · secondary NCT01887600
  • 2.0 vs 0.4 n 312 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.3 n 291 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.3 n 124 · Phase 3 · secondary NCT01887600
  • 0.2 vs 0.1 wk 104 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 100 · n 413 · Phase 3 · secondary NCT02278341
  • 0.1 vs -0.1 wk 96 · n 413 · Phase 3 · secondary NCT02278341
  • 0.4 vs 0.2 wk 92 · n 413 · Phase 3 · secondary NCT02278341
  • 0.0 vs -0.0 wk 88 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 84 · n 413 · Phase 3 · secondary NCT02278341
  • 0.1 vs -0.0 wk 80 · n 413 · Phase 3 · secondary NCT02278341
  • 0.4 vs 0.2 wk 76 · n 413 · Phase 3 · secondary NCT02278341
  • 0.1 vs -0.0 wk 72 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 68 · n 413 · Phase 3 · secondary NCT02278341
  • 0.2 vs -0.1 wk 64 · n 413 · Phase 3 · secondary NCT02278341
  • 0.4 vs 0.2 wk 60 · n 413 · Phase 3 · secondary NCT02278341
  • 0.2 vs 0.1 wk 56 · n 413 · Phase 3 · secondary NCT02278341
  • 2.6 vs 2.4 wk 52 · n 490 · Phase 3 · secondary NCT02052310
  • 0.4 vs 0.2 wk 52 · n 413 · Phase 3 · secondary NCT02278341
  • 0.2 vs 0.1 wk 48 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.3 wk 44 · n 413 · Phase 3 · secondary NCT02278341
  • 0.2 vs 0.1 wk 40 · n 413 · Phase 3 · secondary NCT02278341
  • 0.5 vs 0.2 wk 36 · n 413 · Phase 3 · secondary NCT02278341
  • 0.4 vs 0.1 wk 34 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 32 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 30 · n 413 · Phase 3 · secondary NCT02278341
  • 0.5 vs 0.3 wk 28 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 26 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 24 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 22 · n 413 · Phase 3 · secondary NCT02278341
  • 0.5 vs 0.2 wk 20 · n 413 · Phase 3 · secondary NCT02278341
  • 0.4 vs 0.0 wk 18 · n 413 · Phase 3 · secondary NCT02278341
  • 0.6 vs 0.2 wk 16 · n 413 · Phase 3 · secondary NCT02278341
  • 0.5 vs 0.0 wk 14 · n 413 · Phase 3 · secondary NCT02278341
  • 0.7 vs 0.1 wk 12 · n 413 · Phase 3 · secondary NCT02278341
  • 0.6 vs -0.0 wk 10 · n 413 · Phase 3 · secondary NCT02278341
  • 0.8 vs 0.1 wk 8 · n 413 · Phase 3 · secondary NCT02278341
  • 0.7 vs -0.0 wk 7 · n 413 · Phase 3 · secondary NCT02278341
  • 0.9 vs 0.1 wk 6 · n 413 · Phase 3 · secondary NCT02278341
  • 0.7 vs -0.0 wk 5 · n 413 · Phase 3 · secondary NCT02278341
  • 0.8 vs 0.1 wk 4 · n 413 · Phase 3 · secondary NCT02278341
  • 0.6 vs 0.1 wk 3 · n 413 · Phase 3 · secondary NCT02278341
  • 0.9 vs 0.7 n 836 · Phase 3 · secondary NCT02174731
  • 2.3 vs 2.5 wk 24 · n 228 · Phase 3 · secondary NCT02052310
  • 0.6 vs -0.0 wk 24 · n 189 · Phase 3 · secondary NCT02273726
  • 0.5 vs 0.1 wk 2 · n 413 · Phase 3 · secondary NCT02278341
  • 0.2 vs 0.1 wk 1 · n 413 · Phase 3 · secondary NCT02278341
  • 0.8 vs 0.6 n 280 · Phase 3 · secondary NCT02174731
  • 2.7 vs 2.5 n 435 · Phase 3 · secondary NCT02052310
  • 1.2 vs 0.0 2.0 mg/kg BIW · wk 8 · n 9 · Phase 2 · primary NCT00761657
  • 1.5 vs 0.0 2.0 mg/kg TIW · wk 8 · n 11 · Phase 2 · primary NCT00761657
  • 0.8 vs 0.0 1.5 mg/kg BIW · wk 8 · n 10 · Phase 2 · primary NCT00761657
  • 1.3 vs 0.0 1.5 mg/kg TIW · wk 8 · n 11 · Phase 2 · primary NCT00761657
  • 0.5 vs 0.0 1.0 mg/kg BIW · wk 8 · n 5 · Phase 2 · primary NCT00761657
  • 0.1 vs 0.0 1.0 mg/kg TIW · wk 8 · n 5 · Phase 2 · primary NCT00761657
  • 0.6 vs 0.0 0.7 mg/kg BIW · wk 8 · n 10 · Phase 2 · primary NCT00761657
  • 0.2 vs 0.0 0.7 mg/kg TIW · wk 8 · n 12 · Phase 2 · primary NCT00761657
  • 0.7 vs -2.5 2.0 mg/kg TIW · wk 7 · n 9 · Phase 2 · secondary NCT01147666
  • -2.0 vs -2.4 2.0 mg/kg TIW · wk 12 · n 3 · Phase 2 · secondary NCT01147666
  • -0.4 vs -2.5 1.8 mg/kg TIW · wk 20 · n 6 · Phase 2 · secondary NCT01147666
  • -0.6 vs -2.5 1.8 mg/kg TIW · wk 20 · n 11 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 1.8 mg/kg TIW · wk 19 · n 6 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 1.8 mg/kg TIW · wk 19 · n 11 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 1.8 mg/kg TIW · wk 17 · n 6 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 1.8 mg/kg TIW · wk 17 · n 11 · Phase 2 · secondary NCT01147666
  • 0.5 vs -2.4 1.8 mg/kg TIW · wk 14 · n 6 · Phase 2 · secondary NCT01147666
  • -0.0 vs -2.4 1.8 mg/kg TIW · wk 14 · n 11 · Phase 2 · secondary NCT01147666
  • 0.3 vs -2.4 1.8 mg/kg TIW · wk 12 · n 6 · Phase 2 · secondary NCT01147666
  • 0.0 vs -2.4 1.8 mg/kg TIW · wk 12 · n 11 · Phase 2 · secondary NCT01147666
  • 0.6 vs -2.4 1.8 mg/kg TIW · wk 10 · n 6 · Phase 2 · secondary NCT01147666
  • 0.2 vs -2.4 1.8 mg/kg TIW · wk 10 · n 11 · Phase 2 · secondary NCT01147666
  • 0.5 vs -2.4 1.8 mg/kg TIW · wk 8 · n 6 · Phase 2 · secondary NCT01147666
  • 0.1 vs -2.4 1.8 mg/kg TIW · wk 8 · n 11 · Phase 2 · secondary NCT01147666
  • 0.3 vs -2.5 1.8 mg/kg TIW · wk 7 · n 11 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.5 1.8 mg/kg TIW · wk 7 · n 11 · Phase 2 · secondary NCT01147666
  • 0.9 vs -2.5 1.5 mg/kg TIW · wk 7 · n 10 · Phase 2 · secondary NCT01147666
  • -0.6 vs -2.5 1.3 mg/kg TIW · wk 20 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 1.3 mg/kg TIW · wk 19 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 1.3 mg/kg TIW · wk 17 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 1.3 mg/kg TIW · wk 14 · n 11 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 1.3 mg/kg TIW · wk 12 · n 11 · Phase 2 · secondary NCT01147666
  • -0.2 vs -2.4 1.3 mg/kg TIW · wk 10 · n 11 · Phase 2 · secondary NCT01147666
  • 0.0 vs -2.4 1.3 mg/kg TIW · wk 8 · n 11 · Phase 2 · secondary NCT01147666
  • -0.2 vs -2.5 1.3 mg/kg TIW · wk 7 · n 11 · Phase 2 · secondary NCT01147666
  • -0.4 vs -2.5 1.0 mg/kg TIW · wk 7 · n 9 · Phase 2 · secondary NCT01147666
  • -0.8 vs -2.5 Weight Tiered 70-100-150 mg · wk 20 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.5 Weight Tiered 70-120-200 mg · wk 20 · n 10 · Phase 2 · secondary NCT01147666
  • -0.6 vs -2.5 Weight Tiered 70-120-200 mg · wk 20 · n 10 · Phase 2 · secondary NCT01147666
  • -0.8 vs -2.4 Weight Tiered 70-100-150 mg · wk 19 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 19 · n 10 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 Weight Tiered 70-120-200 mg · wk 19 · n 10 · Phase 2 · secondary NCT01147666
  • -0.5 vs -2.4 Weight Tiered 70-100-150 mg · wk 17 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 17 · n 10 · Phase 2 · secondary NCT01147666
  • 0.0 vs -2.4 Weight Tiered 70-120-200 mg · wk 17 · n 10 · Phase 2 · secondary NCT01147666
  • -0.4 vs -2.4 Weight Tiered 70-100-150 mg · wk 14 · n 11 · Phase 2 · secondary NCT01147666
  • -0.2 vs -2.4 Weight Tiered 70-120-200 mg · wk 14 · n 10 · Phase 2 · secondary NCT01147666
  • 0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 14 · n 10 · Phase 2 · secondary NCT01147666
  • -0.6 vs -2.4 Weight Tiered 70-100-150 mg · wk 12 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 12 · n 10 · Phase 2 · secondary NCT01147666
  • 0.4 vs -2.4 Weight Tiered 70-120-200 mg · wk 12 · n 10 · Phase 2 · secondary NCT01147666
  • -0.6 vs -2.4 Weight Tiered 70-100-150 mg · wk 10 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 10 · n 10 · Phase 2 · secondary NCT01147666
  • 0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 10 · n 10 · Phase 2 · secondary NCT01147666
  • -0.5 vs -2.4 Weight Tiered 70-100-150 mg · wk 8 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 8 · n 10 · Phase 2 · secondary NCT01147666
  • 0.2 vs -2.4 Weight Tiered 70-120-200 mg · wk 8 · n 10 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.5 Weight Tiered 70-100-150 mg · wk 7 · n 11 · Phase 2 · secondary NCT01147666
  • -0.5 vs -2.5 Weight Tiered 70-120-200 mg · wk 7 · n 10 · Phase 2 · secondary NCT01147666
  • 0.2 vs -2.5 Weight Tiered 70-120-200 mg · wk 7 · n 10 · Phase 2 · secondary NCT01147666
  • 0.1 vs -2.5 2.0 mg/kg · wk 20 · n 2 · Phase 2 · secondary NCT01147666
  • -2.8 vs -2.5 2.0 mg/kg TIW · wk 20 · n 3 · Phase 2 · secondary NCT01147666
  • 0.1 vs -2.4 2.0 mg/kg · wk 19 · n 2 · Phase 2 · secondary NCT01147666
  • -3.0 vs -2.4 2.0 mg/kg TIW · wk 19 · n 3 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 2.0 mg/kg · wk 17 · n 2 · Phase 2 · secondary NCT01147666
  • -2.7 vs -2.4 2.0 mg/kg TIW · wk 17 · n 3 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 2.0 mg/kg · wk 14 · n 2 · Phase 2 · secondary NCT01147666
  • -2.3 vs -2.4 2.0 mg/kg TIW · wk 14 · n 3 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 2.0 mg/kg · wk 12 · n 2 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 2.0 mg/kg · wk 10 · n 2 · Phase 2 · secondary NCT01147666
  • -1.5 vs -2.4 2.0 mg/kg TIW · wk 10 · n 3 · Phase 2 · secondary NCT01147666
  • 0.1 vs -2.4 2.0 mg/kg · wk 8 · n 2 · Phase 2 · secondary NCT01147666
  • -0.9 vs -2.4 2.0 mg/kg TIW · wk 8 · n 3 · Phase 2 · secondary NCT01147666
  • 0 vs -2.5 2.0 mg/kg · wk 7 · n 2 · Phase 2 · secondary NCT01147666
  • -0.9 vs -2.5 2.0 mg/kg TIW · wk 7 · n 3 · Phase 2 · secondary NCT01147666
  • -2.6 vs -2.5 1.5 mg/kg TIW · wk 7 · n 1 · Phase 2 · secondary NCT01147666
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. Desidustat: 1 of 5 rows · Roxadustat: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDesidustatRoxadustat
Rows use multiple source trials
Hemoglobin
responder rate · % of participants
77.78% vs 68.48% darbepoetina,b,c
NCT04012957 · Phase 3 · sponsor-reported, not registry data
1 other source trial
59.22% vs 48.37% epoetin alfa
NCT04215120 · Phase 3 · sponsor-reported, not registry data
84.2% (n=386) vs 82.4% (n=397) ESA @ 36wkd,a,b,c
NCT02278341 · Phase 3 · registry result, not featured evidence
show 1 more dose
83.1% (n=413) vs 82.1% (n=420) ESA @ 36wk
NCT02278341 · Phase 3 · registry result, not featured evidence
Dropout rate—
43.3%e
NCT01750190 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 40 more results
22.6%
NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
37.3%
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
7.7%
NCT04655027 · Phase 4 · registry result, not featured evidence
18.2%
NCT04410198 · Phase 3 · registry result, not featured evidence
26.5%
NCT03329196 · Phase 3 · registry result, not featured evidence
25.9%
NCT03439137 · Phase 3 · registry result, not featured evidence
14.3%
NCT03402386 · Phase 3 · registry result, not featured evidence
12.5%
NCT03461146 · Phase 3 · registry result, not featured evidence
6.1%
NCT02174627 · Phase 3 · registry result, not featured evidence
6.6%
NCT02174731 · Phase 3 · registry result, not featured evidence
41.2%
NCT02052310 · Phase 3 · registry result, not featured evidence
65.7%
NCT02273726 · Phase 3 · registry result, not featured evidence
28.4%
NCT02278341 · Phase 3 · registry result, not featured evidence
66.7%
NCT01630889 · Phase 2 · registry result, not featured evidence
8.3%2.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0%2.0 mg/kg
NCT01147666 · Phase 2 · registry result, not featured evidence
80%2.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
16.7%1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
41.7%1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
16.7%1.5 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
50%1.5 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
25%1.3 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
16.7%1.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
20%Weight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
25%Weight Tiered 70-100-150 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
25%Weight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
4.2%100 mg TIW
NCT01244763 · Phase 2 · registry result, not featured evidence
16%70 mg BIW Then QW
NCT01244763 · Phase 2 · registry result, not featured evidence
8.3%50 mg TIW
NCT01244763 · Phase 2 · registry result, not featured evidence
12.5%Tiered, Weight Based Dosing TIW
NCT01244763 · Phase 2 · registry result, not featured evidence
12.5%Tiered, Weight Based Dosing TIW Then BIW
NCT01244763 · Phase 2 · registry result, not featured evidence
12.5%Tiered, Weight Based Dosing BIW Then QW
NCT01244763 · Phase 2 · registry result, not featured evidence
100%2.0 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
50%2.0 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
—1.5 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
—1.5 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
33.3%1.0 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
60%1.0 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
—0.7 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
—0.7 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs—
7.6%e
NCT01750190 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 40 more results
0.6%
NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
5.4%
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
—
NCT04655027 · Phase 4 · registry result, not featured evidence
2%
NCT04410198 · Phase 3 · registry result, not featured evidence
6.6%
NCT03329196 · Phase 3 · registry result, not featured evidence
9.9%
NCT03439137 · Phase 3 · registry result, not featured evidence
7.1%
NCT03402386 · Phase 3 · registry result, not featured evidence
8.3%
NCT03461146 · Phase 3 · registry result, not featured evidence
—
NCT02174627 · Phase 3 · registry result, not featured evidence
—
NCT02174731 · Phase 3 · registry result, not featured evidence
5.6%
NCT02052310 · Phase 3 · registry result, not featured evidence
7.3%
NCT02273726 · Phase 3 · registry result, not featured evidence
0.7%
NCT02278341 · Phase 3 · registry result, not featured evidence
—
NCT01630889 · Phase 2 · registry result, not featured evidence
8.3%2.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0%2.0 mg/kg
NCT01147666 · Phase 2 · registry result, not featured evidence
20%2.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0%1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0%1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
8.3%1.5 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0%1.5 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0%1.3 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
8.3%1.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0%Weight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
0%Weight Tiered 70-100-150 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
0%Weight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
0%100 mg TIW
NCT01244763 · Phase 2 · registry result, not featured evidence
4%70 mg BIW Then QW
NCT01244763 · Phase 2 · registry result, not featured evidence
0%50 mg TIW
NCT01244763 · Phase 2 · registry result, not featured evidence
4.2%Tiered, Weight Based Dosing TIW
NCT01244763 · Phase 2 · registry result, not featured evidence
0%Tiered, Weight Based Dosing TIW Then BIW
NCT01244763 · Phase 2 · registry result, not featured evidence
0%Tiered, Weight Based Dosing BIW Then QW
NCT01244763 · Phase 2 · registry result, not featured evidence
0%2.0 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
0%2.0 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
—1.5 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
—1.5 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
0%1.0 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
10%1.0 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
—0.7 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
—0.7 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
Serious AEs—
52.5%e
NCT01750190 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 40 more results
64.7%
NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
61.6%
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
0%
NCT04655027 · Phase 4 · registry result, not featured evidence
25.6%
NCT04410198 · Phase 3 · registry result, not featured evidence
27.8%
NCT03329196 · Phase 3 · registry result, not featured evidence
25.3%
NCT03439137 · Phase 3 · registry result, not featured evidence
28.6%
NCT03402386 · Phase 3 · registry result, not featured evidence
29.2%
NCT03461146 · Phase 3 · registry result, not featured evidence
57.4%
NCT02174627 · Phase 3 · registry result, not featured evidence
57.6%
NCT02174731 · Phase 3 · registry result, not featured evidence
44.8%
NCT02052310 · Phase 3 · registry result, not featured evidence
65.4%
NCT02273726 · Phase 3 · registry result, not featured evidence
50.7%
NCT02278341 · Phase 3 · registry result, not featured evidence
60%
NCT01630889 · Phase 2 · registry result, not featured evidence
0%2.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0%2.0 mg/kg
NCT01147666 · Phase 2 · registry result, not featured evidence
40%2.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
33.3%1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
41.7%1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
25%1.5 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
50%1.5 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
25%1.3 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0%1.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
30%Weight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
41.7%Weight Tiered 70-100-150 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
25%Weight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
16.7%100 mg TIW
NCT01244763 · Phase 2 · registry result, not featured evidence
40%70 mg BIW Then QW
NCT01244763 · Phase 2 · registry result, not featured evidence
16.7%50 mg TIW
NCT01244763 · Phase 2 · registry result, not featured evidence
12.5%Tiered, Weight Based Dosing TIW
NCT01244763 · Phase 2 · registry result, not featured evidence
16.7%Tiered, Weight Based Dosing TIW Then BIW
NCT01244763 · Phase 2 · registry result, not featured evidence
41.7%Tiered, Weight Based Dosing BIW Then QW
NCT01244763 · Phase 2 · registry result, not featured evidence
0%2.0 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
0%2.0 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
0%1.5 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
0%1.5 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
0%1.0 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
0%1.0 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
0%0.7 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
30.8%0.7 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs—
e
constipation 16.9% (placebo 11.1%)
hyperkalemia 16% (placebo 12.5%)
viral upper respiratory tract infection 15.9% (placebo 13.1%)
NCT01750190 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 40 more results
hypertension 28.8%
oedema peripheral 14.9%
nausea 10.8%
NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
hypertension 21.7% (placebo 13.3%)
oedema peripheral 11.3% (placebo 10.3%)
viral upper respiratory tract infection 9.7% (placebo 4.4%)
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
abdominal infection 7.7%
back pain 7.7%
hyperkalaemia 7.7%
NCT04655027 · Phase 4 · registry result, not featured evidence
diarrhoea 7.4%
cough 5.9%
covid-19 5.4%
NCT04410198 · Phase 3 · registry result, not featured evidence
nasopharyngitis 24.5%
diarrhoea 11.9%
constipation 9.3%
NCT03329196 · Phase 3 · registry result, not featured evidence
nasopharyngitis 45.7%
diarrhoea 15.4%
contusion 13%
NCT03439137 · Phase 3 · registry result, not featured evidence
catheter site infection 21.4%
diarrhoea 19%
nasopharyngitis 14.3%
NCT03402386 · Phase 3 · registry result, not featured evidence
nasopharyngitis 20.8%
shunt stenosis 20.8%
diarrhoea 16.7%
NCT03461146 · Phase 3 · registry result, not featured evidence
urinary tract infection 11% (placebo 6.8%)
hypertension 10.7% (placebo 8.5%)
oedema peripheral 10.4% (placebo 7.7%)
NCT02174627 · Phase 3 · registry result, not featured evidence
diarrhoea 10.9%
hypertension 8.1%
headache 7.5%
NCT02174731 · Phase 3 · registry result, not featured evidence
hypertension 18.4%
diarrhea 13.8%
muscle spasms 11.5%
NCT02052310 · Phase 3 · registry result, not featured evidence
nausea 17%
vomiting 16.2%
hypertension 15.9%
NCT02273726 · Phase 3 · registry result, not featured evidence
hypertension 15.9%
headache 8.7%
diarrhoea 8%
NCT02278341 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 40%
cough 33.3%
abdominal pain 20%
NCT01630889 · Phase 2 · registry result, not featured evidence
2.0 mg/kg TIW
nausea 8.3% (placebo 0%)
anaemia 0% (placebo 25%)
arteriovenous fistula site complication 0% (placebo 0%)
NCT01147666 · Phase 2 · registry result, not featured evidence
2.0 mg/kg
anaemia 0% (placebo 25%)
arteriovenous fistula site complication 0% (placebo 0%)
catheter site pain 0% (placebo 0%)
NCT01147666 · Phase 2 · registry result, not featured evidence
2.0 mg/kg TIW
cough 20% (placebo 0%)
fatigue 20% (placebo 0%)
haemoglobin decreased 20% (placebo 0%)
NCT01147666 · Phase 2 · registry result, not featured evidence
1.8 mg/kg TIW
anaemia 16.7% (placebo 25%)
diarrhoea 16.7% (placebo 0%)
nausea 8.3% (placebo 0%)
NCT01147666 · Phase 2 · registry result, not featured evidence
1.8 mg/kg TIW
diarrhoea 16.7% (placebo 0%)
anaemia 0% (placebo 25%)
arteriovenous fistula site complication 0% (placebo 0%)
NCT01147666 · Phase 2 · registry result, not featured evidence
1.5 mg/kg TIW
diarrhoea 8.3% (placebo 0%)
anaemia 0% (placebo 25%)
arteriovenous fistula site complication 0% (placebo 0%)
NCT01147666 · Phase 2 · registry result, not featured evidence
1.5 mg/kg TIW
anaemia 25% (placebo 25%)
arteriovenous fistula site complication 25% (placebo 0%)
catheter site pain 25% (placebo 0%)
NCT01147666 · Phase 2 · registry result, not featured evidence
1.3 mg/kg TIW
diarrhoea 16.7% (placebo 0%)
anaemia 0% (placebo 25%)
arteriovenous fistula site complication 0% (placebo 0%)
NCT01147666 · Phase 2 · registry result, not featured evidence
1.0 mg/kg TIW
nausea 25% (placebo 0%)
diarrhoea 8.3% (placebo 0%)
anaemia 0% (placebo 25%)
NCT01147666 · Phase 2 · registry result, not featured evidence
Weight Tiered 70-120-200 mg
anaemia 20% (placebo 25%)
nausea 10% (placebo 0%)
arteriovenous fistula site complication 0% (placebo 0%)
NCT01147666 · Phase 2 · registry result, not featured evidence
Weight Tiered 70-100-150 mg
anaemia 8.3% (placebo 25%)
arteriovenous fistula site complication 0% (placebo 0%)
catheter site pain 0% (placebo 0%)
NCT01147666 · Phase 2 · registry result, not featured evidence
Weight Tiered 70-120-200 mg
nausea 16.7% (placebo 0%)
anaemia 0% (placebo 25%)
arteriovenous fistula site complication 0% (placebo 0%)
NCT01147666 · Phase 2 · registry result, not featured evidence
100 mg TIW
nausea 12.5%
diarrhoea 8.3%
headache 8.3%
NCT01244763 · Phase 2 · registry result, not featured evidence
70 mg BIW Then QW
oedema peripheral 16%
urinary tract infection 12%
nasopharyngitis 8%
NCT01244763 · Phase 2 · registry result, not featured evidence
50 mg TIW
oedema peripheral 16.7%
dizziness 12.5%
diarrhoea 8.3%
NCT01244763 · Phase 2 · registry result, not featured evidence
Tiered, Weight Based Dosing TIW
hypertension 16.7%
nausea 16.7%
diarrhoea 12.5%
NCT01244763 · Phase 2 · registry result, not featured evidence
Tiered, Weight Based Dosing TIW Then BIW
oedema peripheral 20.8%
diarrhoea 16.7%
urinary tract infection 16.7%
NCT01244763 · Phase 2 · registry result, not featured evidence
Tiered, Weight Based Dosing BIW Then QW
nausea 20.8%
urinary tract infection 16.7%
constipation 12.5%
NCT01244763 · Phase 2 · registry result, not featured evidence
2.0 mg/kg BIW
fatigue 18.2% (placebo 0%)
back pain 9.1% (placebo 3.6%)
diarrhoea 9.1% (placebo 7.1%)
NCT00761657 · Phase 2 · registry result, not featured evidence
2.0 mg/kg TIW
allergic sinusitis 8.3% (placebo 0%)
benign breast neoplasm 8.3% (placebo 0%)
cystitis 8.3% (placebo 0%)
NCT00761657 · Phase 2 · registry result, not featured evidence
1.5 mg/kg BIW
headache 30% (placebo 3.6%)
hyperkalaemia 20% (placebo 0%)
back pain 10% (placebo 3.6%)
NCT00761657 · Phase 2 · registry result, not featured evidence
1.5 mg/kg TIW
hyperuricaemia 18.2% (placebo 0%)
renal impairment 18.2% (placebo 0%)
acidosis 9.1% (placebo 0%)
NCT00761657 · Phase 2 · registry result, not featured evidence
1.0 mg/kg BIW
diarrhoea 16.7% (placebo 7.1%)
anorexia 8.3% (placebo 0%)
chills 8.3% (placebo 0%)
NCT00761657 · Phase 2 · registry result, not featured evidence
1.0 mg/kg TIW
back pain 22.2% (placebo 3.6%)
prostatitis 16.7% (placebo 0%)
breast cyst 11.1% (placebo 0%)
NCT00761657 · Phase 2 · registry result, not featured evidence
0.7 mg/kg BIW
anaemia 10% (placebo 0%)
hyperkalaemia 10% (placebo 0%)
hypernatraemia 10% (placebo 0%)
NCT00761657 · Phase 2 · registry result, not featured evidence
0.7 mg/kg TIW
diarrhoea 23.1% (placebo 7.1%)
abdominal pain 7.7% (placebo 0%)
abdominal pain upper 7.7% (placebo 0%)
NCT00761657 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cThe assessment timepoint is not available for both results.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. ePopulation comparability has not been reviewed for 38 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Roxadustat

Hemoglobin Ge 10 76.8% (n=608) vs 18.4% (n=305) placebo @ 36wk
event count · % of participants
NCT01750190 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to % from 467 Participants as posted
LDL-C -18.48 vs 0.22 placebo mg/dL @ 28wk
absolute change · mg/dL
NCT01750190 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 2 more results
-23.8 vs -5.39 Epoetin Alfa mg/dL @ 24wk
NCT02052310 · Phase 3 · registry result, not featured evidence
-13.7 vs 1.23 Epoetin Alfa mg/dL @ 28wk
NCT02273726 · Phase 3 · registry result, not featured evidence
eGFR Slope -2.89 vs -3.1 placebo mL @ 52wk
absolute change · mL
NCT01750190 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
Hb 100% (n=9) vs 26.1% (n=23) placebo @ 8wk2.0 mg/kg BIW
responder rate · % of participants
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 9 Participants as posted
show 18 more results
100% (n=11) vs 26.1% (n=23) placebo @ 8wk*2.0 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 11 Participants as posted
100% (n=9) vs 34.8% (n=23) placebo @ 16wk*2.0 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 9 Participants as posted
100% (n=11) vs 34.8% (n=23) placebo @ 16wk*2.0 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 11 Participants as posted
80% (n=10) vs 26.1% (n=23) placebo @ 8wk*1.5 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 8 Participants as posted
90.9% (n=11) vs 26.1% (n=23) placebo @ 8wk*1.5 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 10 Participants as posted
90% (n=10) vs 34.8% (n=23) placebo @ 16wk*1.5 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 9 Participants as posted
90.9% (n=11) vs 34.8% (n=23) placebo @ 16wk*1.5 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 10 Participants as posted
60% (n=5) vs 26.1% (n=23) placebo @ 8wk*1.0 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 3 Participants as posted
40% (n=5) vs 26.1% (n=23) placebo @ 8wk*1.0 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 2 Participants as posted
60% (n=5) vs 34.8% (n=23) placebo @ 16wk*1.0 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 3 Participants as posted
40% (n=5) vs 34.8% (n=23) placebo @ 16wk*1.0 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 2 Participants as posted
50% (n=10) vs 26.1% (n=23) placebo @ 8wk*0.7 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 5 Participants as posted
58.3% (n=12) vs 26.1% (n=23) placebo @ 8wk*0.7 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 7 Participants as posted
70% (n=10) vs 34.8% (n=23) placebo @ 16wk*0.7 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 7 Participants as posted
58.3% (n=12) vs 34.8% (n=23) placebo @ 16wk*0.7 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 7 Participants as posted
89.5% (n=286) vs 78% (n=273) Darbepoetin Alfa @ 24wk
NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
77% (n=1371) vs 8.5% (n=1357) placebo @ 24wk
NCT02174627 · Phase 3 · registry result, not featured evidence
66.1% (n=369) vs 58.6% (n=370) Epoetin Alfa @ 52wk
NCT02273726 · Phase 3 · registry result, not featured evidence
Hb Change 1.848 vs 1.839 Darbepoetin Alfa g/dL @ 36wk
absolute change · g/dL
NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 1 more result
1.718 vs 1.673 Darbepoetin Alfa g/dL @ 52wk
NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
LDL-C -0.352 vs 0.049 Darbepoetin Alfa mmol/L @ 28wk
absolute change · mmol/L
NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 3 more results
-0.38 vs -0.02 placebo mmol/L @ 24wk
NCT02174627 · Phase 3 · registry result, not featured evidence
-0.38 vs -0.05 Epoetin Alfa mmol/L @ 24wk
NCT02174731 · Phase 3 · registry result, not featured evidence
-0.459 vs -0.082 ESA mmol/L @ 28wk
NCT02278341 · Phase 3 · registry result, not featured evidence
SF-36 Physical Functioning 0.913 vs 2.062 Darbepoetin Alfa score @ 28wk
absolute change · score
NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 3 more results
1.344 vs 0.632 placebo score
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
0.14 vs -0.39 placebo score @ 28wk
NCT02174627 · Phase 3 · registry result, not featured evidence
0.05 vs -0.155 ESA score @ 28wk
NCT02278341 · Phase 3 · registry result, not featured evidence
Time to Response 88.8% (n=322) vs 77.7% (n=292) Darbepoetin Alfa @ 24wk
responder rate · % of participants
NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 1 more result
88.2% (n=322) vs 77.4% (n=292) Darbepoetin Alfa @ 24wk
NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
SF-36 Vitality 2.788 vs 1.661 placebo score
absolute change · score
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 2 more results
1.59 vs 1.15 placebo score @ 28wk
NCT02174627 · Phase 3 · registry result, not featured evidence
0.46 vs -0.396 ESA score @ 28wk
NCT02278341 · Phase 3 · registry result, not featured evidence
Arterial Pressure -0.814 vs -1.656 placebo mmHg
absolute change · mmHg
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 2 more results
-0.12 vs 1.15 Epoetin Alfa mmHg @ 12wk
NCT02052310 · Phase 3 · registry result, not featured evidence
0.46 vs 0.04 Epoetin Alfa mmHg @ 28wk
NCT02273726 · Phase 3 · registry result, not featured evidence
eGFR Slope Annualized -2.65 vs -3.24 placebo per year
event rate · per year
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
Hemoglobin Level g/dL 11.106 vs 9.468 placebo g/dL
absolute value · g/dL
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 2 more results
10.984 vs 9.381 placebo g/dL
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
10.816 vs 9.324 placebo g/dL
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3

+ 60 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Desidustat's landscape · Roxadustat's landscape